CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

Now through Dec. 31, donations to Beelieve will be matched to fund Bee participation for schools in under-resourced communitiesBeelieveScripps National Spelling Bee, Scripps Howard Fund launch campaign to empower next generation of spellersCINCINNATI, Oct. 16, 2025 (GLOBE NEWSWIRE) — The Scripps Howard Fund and the Scripps National Spelling Bee have launched “Beelieve,” a new campaign to expand access to the Bee for students from schools in under‑resourced communities. In celebration of the Bee’s 100th anniversary this year, the first $100,000 in donations will be matched by the Adam R. Scripps Foundation. Beelieve will provide free enrollment and program resources to partner Title 1 schools during the 2025-26 school year so even more students can benefit from the Bee’s yearlong program. “Every student deserves the chance...

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it will be presenting at the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub on Wednesday, October 22, 2025 at 9:30 AM (EST) at the Arcadian Loft in Downtown Toronto. Tom Looby, Chief Executive Officer of Conavi Medical, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClubDate: Wednesday, October 22, 2025Time: 9:30 AM (Toronto, ON Local...

HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape pods CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the launch of HYPHEN, driving further momentum for the Company’s expanding vape portfolio with the exclusive rollout of HYPHEN’s all-in-one pod system. With a modular battery design that utilizes pod-functionality to serve multiple oil and volume categories within the same base unit, HYPHEN offers consumers the freedom and flexibility to use a variety of oils, sizes and formats without the hassle of juggling between different devices. Beginning October 18, HYPHEN will hit dispensary shelves across...

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Gene Mack, President and CEO of Gain, will be participating in a live discussion, “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories”, on October 22nd. The panel will include discussion about innovative approaches for a range of neurogenerative diseases that are in active clinical trials, If you are interested in meeting with Gain management, please contact your Maxim sales...

Initial order of ~$1 million, with more revenue expected as deployments expand across South Carolina and beyond COLUMBIA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR) (“Rekor” or the “Company”), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced that South Carolina’s Office of Information Technology (OIT), working in collaboration with the South Carolina State Transport Police (STP) and the South Carolina Department of Transportation (SCDOT), received first place in the State Technology Innovation Award for deploying “virtual weigh stations” powered by Rekor technology and integrated with Drakewell. Rekor will receive an initial order of approximately $1 million related to this technology rollout, with more revenue expected...

Unveiling of Draganfly line at Drone Nerds ElevateUAV 2025 San Diego, CA, Oct. 16, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), an industry-leading developer of drone solutions and systems, today announced that it has appointed Drone Nerds, a leading U.S. drone retailer, integrator, and service provider, as an official value-added reseller (VAR) for its full line of NDAA-compliant unmanned aerial systems. Drone Nerds will provide sales, integration, training, support, and service for Draganfly’s public safety-grade drone systems across the U.S. and allied markets. As part of this arrangement Drone Nerds will display the Draganfly product line at its upcoming ElevateUAV 2025 conference on October 21–22 in Miami, Florida, where Cameron Chell, CEO of Draganfly, will lead a featured session titled “The...

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the pricing of an underwritten offering to a select group of institutional investors consisting of 21,895,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 28,713,500 shares of its common stock. Each share of common stock and each pre-funded warrant...